// App-Quantinova.ai

TPS10142 : A multicenter, randomized, double-blind, placebo-controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.

Researchers

Presenter

  • Li Zhang

Principal Investigators

  • Ting Zhou

  • Yuxiang Ma

  • Yunpeng Yang

  • Wenfeng Fang

  • Yuangyuan Zhao

  • Shaodong Hong

  • Chan Fang

  • Jiexia Zhang

  • Hongyu Zhang

  • Hongyun Zhao

  • Yan Huang

Medical Centers

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • Cancer Center Sun Yat Sen University, Guangzhou, China

  • Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

  • Hospital of Traditional Chinese Medicine of Zhongshan, Zhongshan, China

  • The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, CA, China

  • The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China

  • State Key Laboratory of Oncology in South China, Caner Center, Sun Yat-sen University, Guangzhou, China

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT01882621

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved